Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nitroglycerin
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cosette Pharmaceuticals Announces Approval and Launch Of First Generic Rectiv®
Details : Rectiv-Generic (nitroglycerin) is a nitrate vasodilator activating guanylate cyclase to increase cyclic GMP in smooth muscle. It is indicated for treating moderate to severe chronic anal fissure pain.
Product Name : Rectiv-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 22, 2024
Lead Product(s) : Nitroglycerin
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nitroglycerin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon
Details : Undisclosed
Product Name : Vascana
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 23, 2016
Lead Product(s) : Nitroglycerin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nitroglycerin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : MD Anderson Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Effectiveness of Novel Nitroglycerin Based Catheter Lock Solution
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 16, 2015
Lead Product(s) : Nitroglycerin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : MD Anderson Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nitroglycerin
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Sponsor : Health Research Board, Ireland
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 16, 2015
Lead Product(s) : Nitroglycerin
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Sponsor : Health Research Board, Ireland
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nitroglycerin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Richmond Pharmacology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 13, 2015
Lead Product(s) : Nitroglycerin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Richmond Pharmacology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nitroglycerin
Therapeutic Area : Gastroenterology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetic,Safety and Exploratory Efficacy of RECTIV® in Adolescents With Chronic Anal Fissure
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 09, 2013
Lead Product(s) : Nitroglycerin
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nitroglycerin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Undisclosed
Sponsor : American College of Obstetricians and Gynecologists | Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 12, 2011
Lead Product(s) : Nitroglycerin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Sponsor : American College of Obstetricians and Gynecologists | Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nitroglycerin
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Reliable Cancer Therapies | Anticancer Fund, Belgium
Deal Size : Inapplicable
Deal Type : Inapplicable
Nitroglycerin in Non-small Cell Lung Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 28, 2010
Lead Product(s) : Nitroglycerin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Reliable Cancer Therapies | Anticancer Fund, Belgium
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nitroglycerin
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 15, 2010
Lead Product(s) : Nitroglycerin
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable